Continuous versus intermittent administration of piperacillin–tazobactam in intensive care unit patients with ventilator-associated pneumonia
| Autor: | Seyed Mohammadreza Hashemian, Payam Tabarsi, Arnavaz Akhzarmehr, Hamidreza Jamaati, Shadi Baniasadi, Arvin Najafi, Somayeh Ghafari, Fanak Fahimi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Mechanical ventilation
Piperacillin medicine.medical_specialty business.industry medicine.medical_treatment Mortality rate Ventilator-associated pneumonia Critical Care and Intensive Care Medicine medicine.disease Intensive care unit Tazobactam law.invention Surgery Pneumonia ventilator-associated pneumonia tazobactam law Anesthesia Piperacillin/tazobactam medicine business medicine.drug Research Article |
| Zdroj: | Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine |
| ISSN: | 1998-359X 0972-5229 |
| Popis: | Background and Aims: Ventilator-associated pneumonia (VAP) is one of the most common Intensive Care Unit (ICU)-acquired infection. The aim of this study was to compare the clinical outcome of continuous and intermittent administration of piperacillin-tazobactam by serial measurements of the Clinical Pulmonary Infection Score (CPIS). Subjects and Methods: Groups were designed as parallel and the study was designed as quasi-experimental and conducted at a semi-closed ICU between September 2008 and May 2010. Patients received 3.375 g (piperacillin 3 g/tazobactam 0.375 g) either through intermittent infusion every 6 h for 30 min [Intermittent Infusion (II) group; n = 30] or through continuous infusion every 8 h for 4 h [Continuous Infusion (CI) group; n = 31]. CPIS was used to assess the clinical diagnosis and outcome of VAP patients. Results: Sex, age, Acute Physiology and Chronic Health Evaluation II II score on ICU admission, diagnosis and underlying disease of VAP patients were not significantly different in the CI ( n = 31) and II ( n = 30) groups. Duration of mechanical ventilation, length of stay, total number of antibiotics used per patient and duration of piperacillin/tazobactam treatment were similar in both groups. Mortality rates of VAP patients were similar between both groups during hospitalization. Conclusion: There was no significant difference in clinical outcomes of patients receiving piperacillin-tazobactam via CI or II when measured by serial CPIS score. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|